Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.
Identifieur interne : 001408 ( PubMed/Corpus ); précédent : 001407; suivant : 001409Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.
Auteurs : Jackalina Van Kampen ; Harold Robertson ; Theo Hagg ; Robert DrobitchSource :
- Experimental neurology [ 0014-4886 ] ; 2003.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors), Animals, Dopamine Agents (toxicity), Dose-Response Relationship, Drug, Female, Immunohistochemistry, Locomotion (physiology), Mice, Mice, Inbred C57BL, Neuroprotective Agents, Panax (chemistry), Parkinson Disease, Secondary (pathology), Parkinson Disease, Secondary (physiopathology), Parkinson Disease, Secondary (prevention & control), Phytotherapy, Plant Extracts (therapeutic use), Pyridinium Compounds (toxicity), Rats, Rats, Sprague-Dawley.
- MESH :
- chemical , antagonists & inhibitors : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemical , therapeutic use : Plant Extracts.
- chemical , toxicity : Dopamine Agents, Pyridinium Compounds.
- chemistry : Panax.
- pathology : Parkinson Disease, Secondary.
- physiology : Locomotion.
- physiopathology : Parkinson Disease, Secondary.
- prevention & control : Parkinson Disease, Secondary.
- Animals, Dose-Response Relationship, Drug, Female, Immunohistochemistry, Mice, Mice, Inbred C57BL, Neuroprotective Agents, Phytotherapy, Rats, Rats, Sprague-Dawley.
Abstract
The herbal remedy, ginseng, has recently been demonstrated to possess neurotrophic and neuroprotective properties, which may be useful in preventing various forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's disease (PD). In these studies, we examine the potential neuroprotective actions of the ginseng extract, G115, in two rodent models of PD. Animals received oral administration of G115 prior to and/or following exposure to the parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in mice, or its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP(+)), in rats. Such treatment significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in the substantia nigra and reduced the appearance of locomotor dysfunction. Thus, oral administration of ginseng appears to provide protection against neurotoxicity in rodent models of PD. Further examination of the neuroprotective actions of ginseng and its various elements may provide a potential means of slowing the progress of PD.
PubMed: 14637121
Links to Exploration step
pubmed:14637121Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.</title><author><name sortKey="Van Kampen, Jackalina" sort="Van Kampen, Jackalina" uniqKey="Van Kampen J" first="Jackalina" last="Van Kampen">Jackalina Van Kampen</name><affiliation><nlm:affiliation>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building, Halifax, B3H 4H7, Nova Scotia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Robertson, Harold" sort="Robertson, Harold" uniqKey="Robertson H" first="Harold" last="Robertson">Harold Robertson</name></author><author><name sortKey="Hagg, Theo" sort="Hagg, Theo" uniqKey="Hagg T" first="Theo" last="Hagg">Theo Hagg</name></author><author><name sortKey="Drobitch, Robert" sort="Drobitch, Robert" uniqKey="Drobitch R" first="Robert" last="Drobitch">Robert Drobitch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14637121</idno><idno type="pmid">14637121</idno><idno type="wicri:Area/PubMed/Corpus">001408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001408</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.</title><author><name sortKey="Van Kampen, Jackalina" sort="Van Kampen, Jackalina" uniqKey="Van Kampen J" first="Jackalina" last="Van Kampen">Jackalina Van Kampen</name><affiliation><nlm:affiliation>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building, Halifax, B3H 4H7, Nova Scotia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Robertson, Harold" sort="Robertson, Harold" uniqKey="Robertson H" first="Harold" last="Robertson">Harold Robertson</name></author><author><name sortKey="Hagg, Theo" sort="Hagg, Theo" uniqKey="Hagg T" first="Theo" last="Hagg">Theo Hagg</name></author><author><name sortKey="Drobitch, Robert" sort="Drobitch, Robert" uniqKey="Drobitch R" first="Robert" last="Drobitch">Robert Drobitch</name></author></analytic><series><title level="j">Experimental neurology</title><idno type="ISSN">0014-4886</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors)</term><term>Animals</term><term>Dopamine Agents (toxicity)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Immunohistochemistry</term><term>Locomotion (physiology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Neuroprotective Agents</term><term>Panax (chemistry)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Parkinson Disease, Secondary (prevention & control)</term><term>Phytotherapy</term><term>Plant Extracts (therapeutic use)</term><term>Pyridinium Compounds (toxicity)</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Plant Extracts</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Dopamine Agents</term><term>Pyridinium Compounds</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Panax</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Locomotion</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Immunohistochemistry</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Neuroprotective Agents</term><term>Phytotherapy</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The herbal remedy, ginseng, has recently been demonstrated to possess neurotrophic and neuroprotective properties, which may be useful in preventing various forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's disease (PD). In these studies, we examine the potential neuroprotective actions of the ginseng extract, G115, in two rodent models of PD. Animals received oral administration of G115 prior to and/or following exposure to the parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in mice, or its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP(+)), in rats. Such treatment significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in the substantia nigra and reduced the appearance of locomotor dysfunction. Thus, oral administration of ginseng appears to provide protection against neurotoxicity in rodent models of PD. Further examination of the neuroprotective actions of ginseng and its various elements may provide a potential means of slowing the progress of PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14637121</PMID><DateCreated><Year>2003</Year><Month>11</Month><Day>25</Day></DateCreated><DateCompleted><Year>2004</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-4886</ISSN><JournalIssue CitedMedium="Print"><Volume>184</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Experimental neurology</Title><ISOAbbreviation>Exp. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>521-9</MedlinePgn></Pagination><Abstract><AbstractText>The herbal remedy, ginseng, has recently been demonstrated to possess neurotrophic and neuroprotective properties, which may be useful in preventing various forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's disease (PD). In these studies, we examine the potential neuroprotective actions of the ginseng extract, G115, in two rodent models of PD. Animals received oral administration of G115 prior to and/or following exposure to the parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in mice, or its toxic metabolite, 1-methyl-4-phenylpyridinium (MPP(+)), in rats. Such treatment significantly and dramatically blocked tyrosine hydroxylase-positive cell loss in the substantia nigra and reduced the appearance of locomotor dysfunction. Thus, oral administration of ginseng appears to provide protection against neurotoxicity in rodent models of PD. Further examination of the neuroprotective actions of ginseng and its various elements may provide a potential means of slowing the progress of PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Kampen</LastName><ForeName>Jackalina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy & Neurobiology, Dalhousie University, Tupper Medical Building, Halifax, B3H 4H7, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Harold</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hagg</LastName><ForeName>Theo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Drobitch</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exp Neurol</MedlineTA><NlmUniqueID>0370712</NlmUniqueID><ISSNLinking>0014-4886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011726">Pyridinium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>42850-10-2</RegistryNumber><NameOfSubstance UI="C026560">1-(4-methoxyphenyl)pyridinium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005894" MajorTopicYN="N">Panax</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="Y">Phytotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011726" MajorTopicYN="N">Pyridinium Compounds</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14637121</ArticleId><ArticleId IdType="pii">S0014488603004060</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001408 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001408 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:14637121
|texte= Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:14637121" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |